文献速递乳腺技术与安全PETCT

68Ga标记的修饰型HER2亲和体在乳腺癌中的PET显像:从移植瘤到患者

PET imaging of a 68Ga labeled modified HER2 affibody in breast cancers: from xenografts to patients.
PubMed 文献 · Br J Radiol · 2019-10-08

研究制备68Ga-NOTA-MAL-Cys-MZHER2:342亲和体探针,在HER2不同表达水平的乳腺癌细胞与小鼠移植瘤中行microPET显像并与免疫组化对照,初步用于乳腺癌患者PET/CT显像;HER2高表达移植瘤较HER2低表达肿瘤显像更清晰,患者中HER2阳性原发灶最大标准化摄取值高于HER2阴性原发灶,未见可检测的副作用。

要点

  • HER2高表达BT474移植瘤较HER2低表达MCF-7肿瘤显像更清晰,与免疫组化结果一致。
  • 患者PET显像中HER2阳性原发灶最大标准化摄取值高于HER2阴性原发灶。
  • 除肾脏外健康组织放射性摄取低(低于2% ID/g),未见可检测的副作用。

核心结论

  • 研究表明68Ga标记HER2亲和体具有显著效率,临床前与临床研究支持用68Ga-NOTA-MAL-Cys-MZHER2:342监测乳腺癌HER2水平的可能性。

研究设计与样本

  • 研究为探针制备加临床前与初步临床评价:NOTA-MAL偶联Cys-MZHER2:342经68Ga标记,行体外稳定性与不同HER2水平乳腺癌细胞结合实验。
  • 临床前在荷瘤小鼠行microPET显像与生物分布实验,并以免疫组化分析作为对照。
  • 初步临床研究对乳腺癌患者行68Ga-NOTA-MAL-Cys-MZHER2:342 PET/CT显像。

关键影像表现/征象

  • microPET显像示HER2高表达BT474移植瘤较HER2低表达MCF-7肿瘤显像更清晰,注射后1小时分别为16.12±2.69 ID%/g与1.32±0.19 ID%/g。
  • 除肾脏外健康组织未见明显放射性蓄积(低于2% ID/g)。
  • 患者PET显像中HER2阳性原发灶呈更高对比度检出,最大标准化摄取值为2.16±0.27,HER2阴性原发灶为0.32±0.05。

诊断标准与关键数值

  • 探针经简单螯合法合成,未衰减校正产率为81±5%,放射化学纯度大于95%。
  • HER2状态以免疫组化分析为对照,microPET显像结果与免疫组化分析一致。

临床应用与阅片要点

  • 作者认为该探针可能有助于判断乳腺癌的HER2状态,临床前与临床研究支持其用于监测乳腺癌HER2水平的可能性。

局限性

  • 原文指出18F标记ZHER2:342亲和体虽获初步成功,但合成过程繁琐、产率低及药代动力学不理想可能阻碍临床应用。
  • 原文将患者PET/CT显像研究表述为初步临床研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancers provides promising opportunities for imaging and targeted therapy. Developing HER2 targeted positron emission tomography (PET) probes might be benefit for management of the disease. Small high-affinity scaffold proteins, affibodies, are ideal vectors for imaging HER2 overexpressed tumors. Despite of the initial success on development of 18F labeled ZHER2:342 affibody, the tedious synthesis producers, low yields and unfavorable pharmacokinetics may hinder the clinical use. 68Ga is an attractive positron emitter for PET imaging. A simple preparation of 68Ga labeled ZHER2:342 analog, 68Ga-NOTA-MAL-Cys-MZHER2:342, was reported in the study. The in vivo performances of the tracer for assessing HER2 status in breast cancers were also evaluated.

METHODS: NOTA-MAL conjugated Cys-MZHER2:342 was radiolabeled with 68Ga. The probe was evaluated by in vitro tests including stability and cell binding studies in breast cancer cells with different HER2 levels. In vivo evaluation was performed in mice bearing tumors using microPET imaging and biodistribution experiments. A PET/CT imaging study was initially performed in patients with breast cancers.

RESULTS: The tracer was synthesized in a straightforward chelation method with satisfactory non-decay corrected yield (81±5%) and radiochemical purity (>95%). In vivo micro-PET imaging showed that HER2 high levels expressed BT474 xenografts were more clear visualized than HER2 low levels expressed MCF-7 tumors (16.12 ± 2.69 ID%/g vs 1.32 ± 0.19 ID%/g at 1 h post-injection). The outcome was consistent with the immunohistochemical analysis. No significant radioactivity was accumulated in healthy tissues (less than 2% ID/g) except kidneys. In a preliminary clinical study, 68Ga-NOTA-MAL-Cys-MZHER2:342 PET imaging allowed more high-contrast detection of HER2 positive primary tumors (maximum standardized uptake value = 2.16±0.27) than those in HER2 negative primary focus (maximum standardized uptake value = 0.32±0.05). No detectable side-effects were found.

CONCLUSION: In summary, this study indicates the significant efficiency of the 68Ga labeled HER2 affibody. Preclinical and clinical studies support the possibility of monitoring HER2 levels in breast cancers using 68Ga-NOTA-MAL-Cys-MZHER2:342.

ADVANCES IN KNOWLEDGE: The research investigated the feasibility of a 68Ga labeled HER2 affibody modified with a hydrophilic linker for breast cancer PET imaging. Favorable outcomes showed that the probe might be valuable for determining HER2 status of the disease.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Xu Y, Wang L, Pan D, et al. PET imaging of a 68Ga labeled modified HER2 affibody in breast cancers: from xenografts to patients. Br J Radiol. 2019. PMID: 31593482. doi:10.1259/bjr.20190425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。